Intuitive Surgical reports developments in robotic-assisted minimally invasive care, centered on its da Vinci surgical systems, da Vinci 5, da Vinci SP, and Ion Endoluminal System. Company news commonly covers procedure volume, system placements, installed-base growth, instruments and accessories revenue, operating lease placements, and share repurchase activity.
Updates also include FDA clearances that expand indications for Intuitive platforms, such as cardiac procedures for da Vinci 5 and additional procedures for da Vinci SP. News about the company also reflects completed commercial expansion in Europe, including direct operations for da Vinci and Ion distribution in Southern European markets.
Luna Innovations Incorporated (NASDAQ: LUNA) has announced a new $14.2 million contract with Intuitive Surgical (NASDAQ: ISRG) to supply critical photonic subsystems for advanced robotic surgical systems. This contract underscores Luna's commitment to long-term, recurring sales and highlights the growing role of its technologies in surgical robotics. CEO Scott Graeff emphasized the company's growth potential in this expanding market and the significance of their products, such as the PHOENIX™ tunable laser, in enhancing surgical outcomes.
Intuitive (Nasdaq: ISRG) reported Q2 2022 financial results, highlighting a 4% increase in revenue to $1.52 billion, driven by a 14% growth in da Vinci procedures despite ongoing COVID-19 disruptions. The company placed 279 surgical systems, a 15% decline year-over-year. GAAP net income decreased to $308 million or $0.85 per diluted share, down from $517 million or $1.42 the previous year. The company repurchased $500 million in common stock and increased stock repurchase authorization to $3.5 billion.
Intuitive (Nasdaq: ISRG) has received FDA clearance for the integration of mobile cone-beam CT imaging technology with its Ion Endoluminal System, enhancing robotic bronchoscopy procedures. This collaboration with Siemens Healthineers allows for improved 2D and 3D imaging, increasing diagnostic yield to approximately 80%. Initial studies suggest a 10% improvement in biopsy accuracy when using the Cios Spin with Ion. This advancement aims to enhance early lung cancer diagnosis, which significantly affects survival rates.
Intuitive (Nasdaq: ISRG) reported Q1 2022 results, revealing revenue of $1.49 billion, up 15% from $1.29 billion in Q1 2021. The increase was driven by a 19% rise in da Vinci procedures. The company placed 311 da Vinci Surgical Systems, marking a 4% increase. However, GAAP net income fell to $366 million ($1.00 per share), down from $426 million ($1.17 per share) in the prior year. COVID-19 continued to impact procedure volumes, but customer demand remained strong. The company ended the quarter with $8.40 billion in cash and investments.
Intuitive (Nasdaq: ISRG) reported Q4 2021 revenue of $1.55 billion, a 17% increase from Q4 2020, propelled by a 19% rise in da Vinci procedures. The company shipped 385 da Vinci Surgical Systems, up 18% year-over-year. GAAP net income reached $381 million ($1.04 per diluted share), while non-GAAP net income was $477 million ($1.30 per diluted share). However, the resurgence of COVID-19 impacted procedure volumes. The firm ended the quarter with $8.6 billion in cash and investments.
Intuitive (Nasdaq: ISRG) reported preliminary financial results for Q4 and full year 2021. Q4 revenue reached approximately $1.55 billion, up 17% from $1.33 billion in Q4 2020. Full-year revenue was about $5.71 billion, a 31% increase from 2020. The company shipped 385 da Vinci Surgical Systems in Q4 2021, marking an 18% increase year-over-year. Additionally, da Vinci procedures grew approximately 19% in Q4 2021 compared to 2020. The company also received FDA clearance for a new 8 mm surgical stapler.
Intuitive announced FDA clearance for the SureForm 30 Curved-Tip Stapler, an 8 mm device aimed at enhancing surgical access in various procedures. Set to launch in 2022, this stapler features a 120-degree articulation and integrates SmartFire technology for optimized staple line performance. The tool allows better visualization for surgeons, which can be crucial in complex surgeries. The company is committed to innovating through customer feedback to improve surgical instruments. The launch is anticipated to bolster Intuitive's portfolio in robotic-assisted surgery.
Intuitive Surgical (Nasdaq: ISRG) has reached a significant milestone by surpassing 10 million robotic-assisted surgical procedures performed with its da Vinci surgical systems. This achievement underscores the growing adoption of minimally invasive surgery worldwide, with over 6,500 da Vinci systems installed in 67 countries and more than 55,000 trained surgeons. CEO Gary Guthart emphasized the commitment to continuous innovation, personalized training programs, and enhancing patient outcomes while addressing over 30,000 clinical studies supporting the technology.
Intuitive (Nasdaq: ISRG) announces key executive leadership changes aimed at supporting its growth and advancing minimally invasive care globally. Effective January 1, 2022, Marshall Mohr takes on the role of Executive Vice President for Global Business Services, with Jamie Samath succeeding him as Chief Financial Officer. Dave Rosa is appointed Chief Strategy and Growth Officer, and Henry Charlton becomes Chief Commercial Officer. These appointments reflect a strategic alignment within the company, focusing on operational efficiency, growth opportunities, and enhanced decision-making processes to better serve customers.
Intuitive (Nasdaq: ISRG) reported Q3 2021 financial results, highlighting a 30% increase in revenue to $1.40 billion compared to Q3 2020. The number of da Vinci systems shipped rose 72% to 336, and the total installed base increased to 6,525 systems. Net income reached $381 million ($1.04 per diluted share), up from $314 million in the same quarter last year. The company's cash and investments totaled $8.2 billion, indicating strong operational cash generation.